Globally, tuberculosis infections continue to increase their resistance to antibiotics. Multidrug resistant tuberculosis infections (MDR TB) have progressed to extensively drug resistance status (XDR TB) and the latter have evolved in some parts of the world to totally drug resistant (TDR TB) infections. MDR TB is difficult to treat successfully, and when therapy is ineffective, a single case c...

TO THE EDITOR—We read the metaanalysis by Bastos et al recently published in Clinical Infectious Diseases [1]. Because of our interest in the association of drug susceptibility testing (DST) results for firstand second-line drugs with treatment outcomes in patients with multidrugresistant (MDR) tuberculosis and extensively drug-resistant (XDR) tuberculosis, we carefully read the entire article....

BACKGROUND Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis are emerging worldwide. The Green Light Committee initiative supported programmatic management of drug-resistant tuberculosis in 90 countries. We used estimates from the Preserving Effective TB Treatment Study to predict MDR and XDR tuberculosis trends in four countries with a high burden of MDR tuberculosis:...

Tuberculosis (TB) has severely threatened public health via emerging multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mycobacterium tuberculosis (MTB) strains. For effective TB treatment, rapid, accurate, and multiplex detection of drug resistance is extremely important. However, conventional methods for TB diagnosis are time consuming and have a limited effect on treatment. Nucle...

In 2006, the Australian Mycobacterium Reference Laboratory Network identified 905 bacteriologically confirmed cases of disease caused by members of the Mycobacterium tuberculosis complex. The annual reporting rate was 4.4 cases per 100,000 population. Of the 905 isolates, 903 were Mycobacterium tuberculosis and two were Mycobacterium bovis. Fourteen children aged under 10 years (male n = 5, fem...

XDR (extensively drug-resistant) and pre-XDR tuberculosis (TB) seriously compromise prognosis and treatment possibilities, and inevitably require the use of group V drugs (World Health Organization). The progress of all patients with XDR and pre-XDR TB seen in a specialized unit during 2012 and 2013 and treated with regimens that included at least 6 months of meropenem-clavulanate (MPC), capreo...

Recently, the World Health Organization (WHO) has released a revised definition of extensively drug-resistant (XDR) tuberculosis (TB) that should be used for clinical and surveillance purposes starting from 1 January, 2021 [1, 2]. The previous XDR-TB was TB is resistant to any fluoroquinolone (levofloxacin and/or moxifloxacin) at least one three second-line injectable drugs (SLIs: capreomycin, ...

conclusions this blis with broad-spectrum activity may be a potential agent for the treatment or control of drug-resistant strains of p. aeruginosa infection. results among the 96 isolates of p. aeruginosa, 2 (2.1%), 94 (97.9%), and 63 (65.6%) were non-mdr, mdr, and xdr, respectively, and 1 (1.1%) was pdr. the most effective antibiotics against these isolates were polymyxins and fosfomycin. a b...

Rifampicin-Resistant/Multidrug-Resistant Tuberculosis (RR/MDR-TB) is recognized as a major public health concern globally. In Armenia, the proportion of RR/MDR-TB increasing among all people affected with TB. We conducted nationwide cohort study involving analysis programmatic data to investigate rates and factors associated unfavourable treatment outcomes patients registered by national TB pro...

Tuberculosis (TB) is a serious infectious disease caused by a bacterial pathogen. Mortality from tuberculosis was estimated at 1.5 million deaths worldwide in 2013. Development of new TB drugs is needed to not only to shorten the medication period but also to treat multi-drug resistant and extensively drug-resistant TB. Mycobacterium tuberculosis (Mtb) grows slowly and only multiplies once or t...